Navigation Links
Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Date:1/7/2008

TAMPA, Fla., Jan. 7 /PRNewswire/ -- Romark Laboratories, L.C., a privately-owned biotechnology company, today announced that Emmet B. Keeffe, M.D., M.A.C.P., has joined the Company as Vice President and Chief Medical Officer.

Most recently, Dr. Keeffe served as Professor of Medicine, Chief of Hepatology and Co-Director of the Liver Transplant Program at Stanford University Medical Center. He is a past-president of the American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy, and served as chair of the Subspecialty Board on Gastroenterology for the American Board of Internal Medicine. He is a Master of the American College of Physicians and a Fellow of the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, the American College of Gastroenterology, and the Royal College of Physicians of Ireland.

"Romark's drug discovery research and ongoing clinical development programs offer the promise of new drugs that could change paradigms for treating viral hepatitis," said Dr. Keeffe. "I am excited to have the opportunity to contribute to the advancement of new therapies in this field."

Dr. Keeffe's research interests include antiviral therapy of chronic hepatitis B and C, use of hepatitis vaccines, and liver transplant selection criteria and outcomes. Throughout his career, he has been an active clinical investigator, with a major focus on novel treatment of chronic viral hepatitis and has published more than 500 papers, book chapters and miscellaneous publications. He lectures widely at national and international scientific meetings, and postgraduate courses.

"We are pleased that Dr. Keeffe has chosen to join our Company," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark. "His expertise in the fields of hepatology and gastroenterology will be invaluable as we advance the development of nitazoxanide and other thiazolides for treating viral hepatitis and other digestive diseases."

About Romark Laboratories

Romark Laboratories, L.C. (http://www.romark.com) is a biotechnology company committed to the discovery and development of innovative new small molecules for treating infectious diseases, cancers, and autoimmune diseases. The Company is developing nitazoxanide for treating chronic hepatitis C and is developing other new thiazolides for treating viral diseases including chronic hepatitis B and C, and influenza.


'/>"/>
SOURCE Romark Laboratories, L.C.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
3. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
4. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
5. ARUP Laboratories Releases ARUP Consult(R) 2.0
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
7. Stiefel Laboratories Appoints Two New Members to Board of Directors
8. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
9. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
10. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
11. Codexis Appoints Singapore Laboratories Managing Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... ... CallTower is proud to announce that their hosted Skype for ... for 2017. , For three consecutive years, CallTower has been recognized by INTERNET ... with the hosted VoIP Excellence award and in 2015, they received the Skype for ...
(Date:1/21/2017)... Jan. 20, 2017 Interpace Diagnostics Group, ... that provides clinically useful molecular diagnostic tests and ... into a securities purchase agreement with three  institutional ... of common stock in a registered direct offering.  ... agreed to sell to the same investors warrants ...
(Date:1/20/2017)... ... ... The two newest companies to join the University City Science Center’s Port ... The Wistar Institute, and Sanguis, launched by a trio of students from the University ... is developing a treatment for a chronic viral infection and its associated diseases, with ...
(Date:1/20/2017)... (PRWEB) , ... January 20, ... ... in Less Exposure Surgery (LES®) Technologies, announced today the next evolution in ... Pedicle Screw System platform). In contrast to the competition, SpineFrontier is focused ...
Breaking Biology Technology:
(Date:1/11/2017)... Intoxalock, a leading ignition interlock provider, has ... patent-pending calibration device. With this new technology, Intoxalock is ... data logs and process repairs at service center locations, ... drunk driving through the application of cutting-edge technologies is ... also for the customer who can get back on ...
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:12/22/2016)... Dec. 20, 2016  As part of its longstanding mission ... personal genetics company, recently released its latest children,s book, titled ... book focuses on the topics of inheritance and variation of ... (NGSS) taught in elementary school classrooms in the US. ... by illustrator Ariana Killoran , whose previous book with ...
Breaking Biology News(10 mins):